The dermatitis drugs market consists of sales of dermatitis drugs such as corticosteroids, calcineurin inhibitors, PDE4 inhibitors which are used to cure inflammation of the outer layer of the body, characterized by itchy rashes on swollen and reddened skin. Some of the major dermatitis drugs include Triamcinolone, Clobetasol, Betamethasone, Hydrocortisone, Fluocinonide and Clobex.
The global dermatitis drugs market is expected to decline from $5.4 billion in 2019 to $4.7 billion in 2020 at a compound annual growth rate (CAGR) of -13.9%. The decline is mainly because of drop in sales due to the lockdown measures to contain COVID-19 spread. Apart from restricting non-emergency medical services, new rules of the governments across the globe has forced many companies in the dermatology drug market to halt their business operations which has impacted the market growth. The market is then expected to recover and grow at a CAGR of 5.7% from 2021 and reach $7.1 billion in 2023.